Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.70 Analyst target: $3.33 Upside: 377.37%
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company is headquartered in Purchase, New York.
See the full interactive analysis & chart →Informational only — not investment advice.